MEDVi's $1.8 Billion Growth Built on AI-and Threatened by It
MEDVi, an online provider of GLP-1 weight-loss drugs, closed 2025 with $401 million in sales and is tracking toward $1.8 billion in 2026. Founder Matthew Gallagher built the company from his house using AI tools for coding, backend systems, and customer service. He started with $20,000 and brought in his brother, Elliot, to form a two-person operation supported by outsourced partners.
The company's rapid growth caught the attention of Sam Altman, who said he had "won a bet" with tech CEOs on when a single-person AI-powered company would emerge. A New York Times profile amplified MEDVi's profile, describing how one man and his brother built a $1.8 billion company with AI.
Then the problems surfaced.
Fake Doctors, Fabricated Results
Business Insider, Forbes, and investigative creators like Coffeezilla alleged MEDVi used AI-generated before-and-after photos, fabricated client stories, and misleading marketing to sell weight-loss drugs. The New York Times acknowledged the deception in its own reporting, noting that MEDVi's initial website featured "photos of smiling models who looked A.I.-generated" and before-and-after images with altered faces sourced from around the web.
The company also ran ads featuring AI-generated testimonials from clients and doctors on TikTok and Facebook-some with visible glitches that gave away their artificial origin. In some cases, doctors featured on the website either didn't exist or were unaware their identities were being used.
FDA Steps In
Regulatory pressure followed. The FDA cited MEDVi for deceptive product labeling, unauthorized claims equating compounded drugs with branded GLP-1s, and improper interstate distribution practices. The agency warned that failure to address violations could result in seizure or injunction.
FDA scrutiny now threatens the company's entire business model and operational ability.
MEDVi's Response
MEDVi said it had not received a formal FDA warning and attributed online references to a third-party affiliate using outdated content. The company said the FDA letter cited a URL resembling its brand but was directed at an affiliate marketing agency, not MEDVi itself.
On AI-generated doctors in advertising, MEDVi acknowledged identifying the issue and said it had updated marketing practices. "We have updated our marketing practices to make clear that this type of advertising and promotion is prohibited," the company said.
Gallagher posted on LinkedIn describing the company's growth as involving "many learning moments" and said he had "course-corrected immediately and appropriately" at each stage. He pointed to The New York Times' access to MEDVi's operations as evidence of transparent practices.
The Lesson for Sales Teams
MEDVi's trajectory illustrates a critical tension for sales organizations using AI for Sales: speed and scale can mask compliance gaps until regulators notice. The company's AI for Marketing approach-generating testimonials, images, and doctor profiles-accelerated customer acquisition but created legal liability that now threatens the business itself.
For sales professionals, the takeaway is straightforward: AI-driven growth that relies on deceptive content is not sustainable growth. Regulatory action, media scrutiny, and reputational damage cost far more than the revenue gained.
Your membership also unlocks:
